Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Classical hematology 1

Conditions

Patient Participation 1Multiple Myeloma 1Lymphoma 1Febrile Neutropenia 1

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 267Melphalan 212Calcium Dobesilate 189fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 44Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × TKN732 × Plasma cell × Clear all
NCT06116734 2023-11-03

Lapelga vs Gastrofil

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 3 Unknown
74 enrolled
Classical hematologyLymphoidPlasma cell

Lymphoma, Multiple Myeloma, Patient Participation, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡